Agenus Inc.

Symbol: AGEN

NASDAQ

11.72

USD

Market price today

  • -0.9789

    P/E Ratio

  • -0.0330

    PEG Ratio

  • 237.74M

    MRK Cap

  • 0.00%

    DIV Yield

Agenus Inc. (AGEN) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.28%

Operating Profit Margin

-0.86%

Net Profit Margin

-1.51%

Return on Assets

-0.95%

Return on Equity

2.19%

Return on Capital Employed

-248.20%

Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Dr. Garo H. Armen Ph.D.
Full-time employees:389
City:Lexington
Address:3 Forbes Road
IPO:2000-02-08
CIK:0001098972

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

General Outlook

When we look at how much money they make before expenses, they keep 0.276% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.856%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -1.511%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.951% return, is a testament to Agenus Inc.'s adeptness in optimizing resource deployment. Agenus Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 2.192%. Furthermore, the proficiency of Agenus Inc. in capital utilization is underscored by a remarkable -248.201% return on capital employed.

Stock Prices

Agenus Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $13.67, while its low point bottomed out at $11.76. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Agenus Inc.'s stock market.

Liquidity Ratios

Analyzing AGEN liquidity ratios reveals its financial health of the firm. The current ratio of 23.57% gauges short-term asset coverage for liabilities. The quick ratio (20.83%) assesses immediate liquidity, while the cash ratio (20.65%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio23.57%
Quick Ratio20.83%
Cash Ratio20.65%

Profitability Ratios

AGEN profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -153.94% underscores its earnings before tax deductions. The effective tax rate stands at -14.08%, revealing its tax efficiency. The net income per EBT, 98.14%, and the EBT per EBIT, 179.74%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -85.65%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-153.94%
Effective Tax Rate-14.08%
Net Income per EBT98.14%
EBT per EBIT179.74%
EBIT per Revenue-85.65%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 0.24, it details the span from stock purchase to revenue.

cards.indicatorcards.value
Days of Sales Outstanding21
Operating Cycle1.08
Days of Payables Outstanding158
Cash Conversion Cycle-157
Receivables Turnover339.11
Payables Turnover2.31
Fixed Asset Turnover0.99
Asset Turnover0.63

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -9.25, and free cash flow per share, -9.38, depict cash generation on a per-share basis. The cash per share value, 2.60, showcases liquidity position. Lastly, the operating cash flow sales ratio, -1.17, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share-9.25
Free Cash Flow per Share-9.38
Cash per Share2.60
Operating Cash Flow Sales Ratio-1.17
Free Cash Flow to Operating Cash Flow Ratio1.01
Cash Flow Coverage Ratio-3.05
Capital Expenditure Coverage Ratio-69.33
Dividend Paid and Capex Coverage Ratio-69.33

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 24.07%, highlights its total liabilities relative to assets. With a debt-equity ratio of -0.99, we discern the balance between debt and equity financing. The long-term debt to capitalization, -10538.57%, and total debt to capitalization, -10538.57%, ratios shed light on its capital structure. An interest coverage of -2.59 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio24.07%
Debt Equity Ratio-0.99
Long Term Debt to Capitalization-10538.57%
Total Debt to Capitalization-10538.57%
Interest Coverage-2.59
Cash Flow to Debt Ratio-3.05
Company Equity Multiplier-4.12

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 0.44, provides a glimpse into top-line earnings distributed across each share. Net income per share, -0.69, reflects the portion of profit attributed to each share. The book value per share, -0.45, represents the net asset value distributed per share, while the tangible book value per share, -0.50, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share0.44
Net Income Per Share-0.69
Book Value Per Share-0.45
Tangible Book Value Per Share-0.50
Shareholders Equity Per Share-0.45
Interest Debt Per Share1.06
Capex Per Share-0.03

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 59.47%, indicates top-line expansion, while the gross profit growth, 240.69%, reveals profitability trends. EBIT growth, 10.77%, and operating income growth, 10.77%, offer insights into operational profitability progression. The net income growth, 9.49%, showcases bottom-line expansion, and the EPS growth, 28.13%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth59.47%
Gross Profit Growth240.69%
EBIT Growth10.77%
Operating Income Growth10.77%
Net Income Growth9.49%
EPS Growth28.13%
EPS Diluted Growth28.13%
Weighted Average Shares Growth27.03%
Weighted Average Shares Diluted Growth27.03%
Operating Cash Flow Growth-27.84%
Free Cash Flow Growth-2.50%
10-Year Revenue Growth per Share326.95%
5-Year Revenue Growth per Share31.53%
3-Year Revenue Growth per Share-14.55%
10-Year Operating CF Growth per Share4.54%
5-Year Operating CF Growth per Share47.07%
3-Year Operating CF Growth per Share22.31%
10-Year Net Income Growth per Share32.03%
5-Year Net Income Growth per Share52.37%
3-Year Net Income Growth per Share50.67%
10-Year Shareholders Equity Growth per Share-197.58%
5-Year Shareholders Equity Growth per Share71.23%
3-Year Shareholders Equity Growth per Share62.06%
Receivables Growth842.58%
Inventory Growth-100.00%
Asset Growth-24.09%
Book Value per Share Growth-105.98%
Debt Growth346.58%
R&D Expense Growth1281.85%
SGA Expenses Growth-19.57%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 6,200,777,840, captures the company's total value, considering both debt and equity. Income quality, 0.91, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.50, gauges operational efficiency, while the research and development to revenue, 150.06%, highlights investment in innovation. The ratio of intangibles to total assets, 9.28%, indicates the value of non-physical assets, and capex to operating cash flow, 4.44%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value6,200,777,840
Income Quality0.91
Sales General and Administrative to Revenue0.50
Research and Development to Revenue150.06%
Intangibles to Total Assets9.28%
Capex to Operating Cash Flow4.44%
Capex to Revenue-6.37%
Capex to Depreciation-73.26%
Stock-Based Compensation to Revenue14.63%
Graham Number2.63
Return on Tangible Assets-86.30%
Graham Net Net-1.02
Working Capital-143,481,000
Tangible Asset Value-177,516,000
Net Current Asset Value-349,879,000
Invested Capital-2
Average Receivables14,288,500
Average Payables51,192,500
Average Inventory6,914,500.5
Days Sales Outstanding60
Days Payables Outstanding1343
ROIC-124.58%
ROE1.53%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, -3.83, and the price to book ratio, -3.83, reflect the market's valuation relative to the company's book value. The price to sales ratio, 1.47, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -1.24, and price to operating cash flows, -1.27, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio-3.83
Price to Book Ratio-3.83
Price to Sales Ratio1.47
Price Cash Flow Ratio-1.27
Price Earnings to Growth Ratio-0.03
Enterprise Value Multiple-1.82
Price Fair Value-3.83
Price to Operating Cash Flow Ratio-1.27
Price to Free Cash Flows Ratio-1.24
Price to Tangible Book Ratio-36.97
Enterprise Value to Sales39.67
Enterprise Value Over EBITDA-42.32
EV to Operating Cash Flow-27.66
Earnings Yield-4.15%
Free Cash Flow Yield-3.95%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Agenus Inc. (AGEN) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -0.979 in 2024.

What is the ticker symbol of Agenus Inc. stock?

The ticker symbol of Agenus Inc. stock is AGEN.

What is company IPO date?

IPO date of Agenus Inc. is 2000-02-08.

What is company current share price?

Current share price is 11.720 USD.

What is stock market cap today?

The market cap of stock today is 237736684.000.

What is PEG ratio in 2024?

The current -0.033 is -0.033 in 2024.

What is the number of employees in 2024?

In 2024 the company has 389.